"10.1371_journal.pone.0050347","plos one","2012-11-29T00:00:00Z","Jan-Patrick Stellmann; Anneke Neuhaus; Lena Herich; Sven Schippling; Matthias Roeckel; Martin Daumer; Roland Martin; Christoph Heesen","Institute for Neuroimmunology and Clinical MS Research (inims) and Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Sylvia Lawry Centre for Multiple Sclerosis Research, Munich, Germany; Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Teva Pharma GmbH, Ulm/Mörfelden-Walldorf, Germany; Neurology Clinic, Department of Clinical Neuroimmunology and Multiple Sclerosis Research, University Medical Center Zürich, Zürich, Switzerland","Conceived and designed the experiments: J-PS LH AN CH MD SS RM. Analyzed the data: J-PS AN LH. Contributed reagents/materials/analysis tools: MR. Wrote the paper: J-PS LH AN CH MD SS MR.","J-PS, Christoph Heesen, SS and RM have received payment for lectures including service on speakers bureaus as well as travel/accomodation/meeting expenses (unrelated to the activities listed) from GlaxoSmithKline, Merck, Novartis, Biogen Idec, Teva. MD, Scientific Director of the Sylvia Lawry Centre for Multiple Sclerosis Research e.V. (SLC) and one of the two Managing Directors of Trium Analysis Online GmbH, serves on the Editorial Board of MedNous and holds Patent 10 2007 044 705.3–35, German patent and trademark office 307 19 449.3/09. The Sylvia Lawry Centre received honoraria for interviews of MD with Propagate Pharma Limited and Deerfield Research LLC; is Medical Advisor of the German Multiple Sclerosis Society; received honoraria for consultancy, statistical analysis and use of actibeltH technology from the following entities: Bayer Schering, Biopartners, Biogen Idec, Biogenerix, Böhringer-Ingelheim, EISAI Limited, Heron Evidence Development Ltd, Hoffmann-La Roche, Johnson & Johnson Pharmaceutical Research & Development LLC, Sanofi-Aventis U.S. INC., Novartis Pharma GmbH, University of Oxford, Imperial College London, University of Southampton, Charite Berlin, University of Vienna, Greencoat Ltd, University Medical Center Hamburg-Eppendorf; serves on the advisory board for EPOSA study and received research grants from the following governmental entities: Federal Ministry of Education and Research Grant No 01GI0904, 01GI0920, Mayo Clinic Rochester, European Union (for SLC and Trium) Grant No 215820, European Union (for SLC) Grant No 223865, Federal Ministry of Economics and Technology Grant No KF0564001KF7, University of Oxford, Technical University of Munich, Hertie Foundation Grant No 1.01.1/07/015, Bavarian Research Foundation, National Multiple Sclerosis Society (NMSS), Porticus Foundation Grant No 900.50578, European Union Grant No LSHM-CT-2006–03759, University of Rochester, European Union Grant No LSHM-CT-2004–503485. AN is employee of the Sylvia Lawry Centre for Multiple Sclerosis Research. MR is employee of Teva Pharma. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.","2012","11","Jan-Patrick Stellmann","JPS",8,TRUE,7,NA,3,7,TRUE,TRUE,FALSE,0,NA,FALSE
